Rx Product News (May 2016)

Pharmacy TimesMay 2016 Skin & Eye Health
Volume 82
Issue 5

Read about the new Rx Products featured in May.

Promius Pharma, LLC

Indication: The FDA has approved Sernivo (betamethasone dipropionate) for the treatment of mild to moderate plaque psoriasis in patients 18 years or older. The commercial launch of the product is planned for the coming quarter.

Dosage Form: Spray: 0.05%

For More Information: drreddys.com

Zembrace SymTouchMarketed by: Promius Pharma, LLC

Indication: The FDA has approved Zembrace SymTouch (sumatriptan succinate) for acute treatment of migraine with or without aura in adults. The product should be used only if a clear diagnosis of migraine has been established; it is not indicated for the prophylactic therapy of migraine. The maximum dose in a 24-hour period is 12 mg. Doses should be separated by at least 1 hour.

Dosage Form: Injection: 3-mg prefilled, ready-to use, single-dose disposable autoinjector

For More Information: zembrace.com

Aczone Gel, 7.5%Marketed by: Allergan

Indication: Allergan has received FDA approval to market Aczone (dapsone) Gel, 7.5%, for acne in patients 12 years and older. The product has proved effective for treating inflammatory and noninflammatory acne with a once-daily application.

Dosage Form: Gel: 7.5%

For More Information: aczone.com

XeljanzMarketed by: Pfizer Labs

Indication: The FDA has approved Xeljanz (tofacitinib citrate) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs.

Dosage Form: Tablets: 5 or 11 mg

For More Information: ra.xeljanz.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.